Ovid Therapeutics Files 2024 Annual Report Amendment

TL;DR

Ovid Therapeutics filed an amendment to its 2024 10-K on 4/30/25.

AI Summary

Ovid Therapeutics Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. This amendment, filed on April 30, 2025, provides updated information for the SEC. The company, headquartered in New York, operates in the pharmaceutical preparations sector.

Why It Matters

This filing provides updated financial and operational information for Ovid Therapeutics Inc., which is crucial for investors and stakeholders to assess the company's performance and outlook.

Risk Assessment

Risk Level: low — This is a routine amendment to an annual report, not indicating new or elevated risks.

Key Numbers

• 2024 — Fiscal Year End (The period covered by the annual report.)
• 001-38085 — Commission File Number (Identifies the company's filings with the SEC.)

Key Players & Entities

• Ovid Therapeutics Inc. (company) — Registrant
• 2024 (date) — Fiscal Year End
• April 30, 2025 (date) — Filing Date
• New York (location) — Business Address City
• 2834 (industry_code) — Standard Industrial Classification

FAQ

From the Filing

0001628280-25-021055.txt : 20250430 0001628280-25-021055.hdr.sgml : 20250430 20250430160612 ACCESSION NUMBER: 0001628280-25-021055 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250430 DATE AS OF CHANGE: 20250430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ovid Therapeutics Inc. CENTRAL INDEX KEY: 0001636651 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 465270895 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38085 FILM NUMBER: 25894979 BUSINESS ADDRESS: STREET 1: 441 NINTH AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 212-776-4381 MAIL ADDRESS: STREET 1: 441 NINTH AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 10-K/A 1 ovid-20241231.htm 10-K/A ovid-20241231 true 0001636651 2024 FY iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 0001636651 2024-01-01 2024-12-31 0001636651 2024-06-30 0001636651 2025-03-07 0001636651 us-gaap:EmployeeStockOptionMember ovid:MargaretAlexanderMember 2024-07-30 0001636651 us-gaap:EmployeeStockOptionMember ovid:JeffreyRonaMember 2024-07-30 0001636651 us-gaap:EmployeeStockOptionMember ovid:MargaretAlexanderMember 2024-09-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________ FORM 10-K/A (Amendment No. 1) _________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31 , 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from         to         Commission File Number: 001-38085 __________________________________ Ovid Therapeutics Inc. (Exact name of Registrant as specified in its charter) __________________________________ Delaware 2834 46-5270895 (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 441 Ninth Avenue, 14th Floor New York , New York 10001 ( 646 ) 661-7661 (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   OVID   The Nasdaq Stock Market LLC Securities registered pursuant to Section 12(g) of the Act: None _____________________________________ I ndicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No x Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Act. Yes o No x Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to the filing requirements for the past 90 days. Yes x No o Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,&#82